Filters
Close
ADDED DATE
Added date
TOPICS Please select
WATCH / LISTEN / READ TIME
Author(s): William Herrington Added: 1 year ago
Long-term cardio-renal outcomes investigating empagliflozin (Boehringer Ingelheim) on kidney disease progression (KDP) or cardiovascular death in patients with pre-existing chronic kidney disease.In this short interview, Prof William Herrington (Nuffield Department of Population Health, University of Oxford, Oxford, UK) discusses the findings from EMPA-KIDNEY (NCT03594110).EMPA-KIDNEY is an… View more
Prof Carlos Morillo is a cardiac electrophysiologist, currently serving in the Chief Division of Cardiology at theLibin Cardiovascular Institute, University of Calgary, Calgary, Alberta, Canada. Prof Morillo has extensively researched Chagas disease since 1990, and was involved in the initial studies related to autonomic control in the different stages of the disease and the use of beta… View more
Author(s): Shrilla Banerjee , Mirvat Alasnag , Marta Kałuzna-Oleksy , et al Added: 1 year ago
In this video, Dr Marta Kałużna-Oleksy is joined by Dr Mirvat Alasnag, Dr Shrilla Banerjee and Dr Michal Hawranek to discuss strategies for heart failure management, based on a presentation at the Prevention and Intervention meeting in 2024.The faculty discuss SCAD, MINOCA and holistic approaches to managing these conditions, including lifestyle factors, hypertension and diabetes. They outline… View more
Author(s): Chim C Lang , Bianca Rocca , Samira Bell Added: 5 months ago
In this short discussion, join Prof Chim Lang (University of Dundee, Dundee, UK), Guest Editor of the upcoming Special Focus on Obesity in Focus, Prof Bianca Rocca (LUM University, Casamassima, IT) and Dr Samira Bell (University of Dundee, Dundee, UK) to discover the implications of obesity on heart failure, kidney disease, and pharmacology.This conversation sets the stage for the upcoming… View more
Author(s): Marianna Fontana Added: 9 months ago
ESC HF 25 - A study investigating CRISPR gene editing with nexiguran ziclumeran in ATTR cardiomyopathy demonstrated favourable safety and tolerability, with consistent reductions in serum TTR in both wild-type and variant disease.Prof Marianna Fontana (University College London, UK) joins us to discuss the key findings from a two-part, open-label, phase 1 study investigating the treatment effect,… View more
Author(s): Ramón Luengo-Fernández Added: 2 years ago
ESC 2023 — Dr Ramón Luengo-Fernández (University of Oxford, UK) joins us on-site to discuss the findings from a registry which aimed to analyse the economic burden of cardiovascular disease within the EU. This was the first study to utilise Europe-wide patient registries and included the costs of long-term social care. Results from the registry found that cardiovascular disease cost the EU €282… View more
Author(s): A Michael Lincoff , Ahmed Ghoneem Added: 2 years ago
AHA 2023 - Investigator, Dr A Michael Lincoff (Cleveland Clinic, US) is interviewed by Dr Ahmed Ghoneem (UPMC Harrisburg, US), CardioNerds Ambassador, on the findings of the SELECT Trial (NCT03574597).SELECT is a randomised trial aiming to determine if semaglutide can reduce the risk of cardiovascular events in patients with overweight or obesity and prior cardiovascular disease. 17609 patients… View more